title: Different expression of mu-opiate receptor in chronic and acute wounds and the effect of beta-endorphin on transforming growth factor beta type II receptor and cytokeratin 16 expression.
abstract: There is evidence that neuropeptides, especially the opiate receptor agonists, are involved in wound healing. We have previously observed that beta-endorphin, the endogenous ligand for the mu-opiate receptor, stimulates the expression of cytokeratin 16 in a dose-dependent manner in human skin organ cultures. Cytokeratin 16 is expressed in hyperproliferative epidermis such as psoriasis and wound healing. Therefore we were interested to study whether epidermal mu-opiate receptor expression is changed at the wound margins in acute and chronic wounds. Using classical and confocal microscopy, we were able to compare the expression level of mu-opiate receptors and the influence of beta-endorphin on transforming growth factor beta type II receptor in organ culture. Our results show indeed a significantly decreased expression of mu-opiate receptors on keratinocytes close to the wound margin of chronic wounds compared to acute wounds. Additionally beta-endorphin upregulates the expression of transforming growth factor beta type II receptor in human skin organ cultures. These results suggest a crucial role of opioid peptides not only in pain control but also in wound healing. Opioid peptides have already been used in animal models in treatment of wounds; they induce fibroblast proliferation and growth of capillaries, and accelerate the maturation of granulation tissue and the epithelization of the defect. Furthermore opioid peptides may fine-tune pain and the inflammatory response while healing takes place. This new knowledge could potentially be used to design new locally applied drugs to improve the healing of painful chronic wounds.
authors.affiliation: Department of Dermatology, University of Basel and Kantonsspital Schauffhausen, Switzerland. paul.bigliardi@kssh.ch
authors.forename: P L
authors.initials: PL
authors.lastname: Bigliardi
authors.forename: L T
authors.initials: LT
authors.lastname: Sumanovski
authors.forename: S
authors.initials: S
authors.lastname: Büchner
authors.forename: T
authors.initials: T
authors.lastname: Rufli
authors.forename: M
authors.initials: M
authors.lastname: Bigliardi-Qi
mesh_terms: D000208:Acute Disease; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D007633:Keratins / Q000235:genetics*; D009924:Organ Culture Techniques; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II; D017450:Receptors, Opioid, mu / Q000032:analysis*; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics*; D014945:Wound Healing; D014947:Wounds and Injuries / Q000378:metabolism*; D001615:beta-Endorphin / Q000494:pharmacology*
chemical_list: D017450:Receptors, Opioid, mu; D018125:Receptors, Transforming Growth Factor beta; D001615:beta-Endorphin; D007633:Keratins; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II